HPV HANDBOOK - Zervita

INDEXuse in ASCUS 53use to confirm cure 31HPV testing plus cytology,advantages 30studies in Costa Rica Mexico andChina 31HPV vaccine, development of 62Iceland, mortality and incidence in 18incidence,in Europe 17of cervical cancer 36of HPV infection 36protective effect of Pap smear 18invasive cervical cancer, incidence in UK 18Ireland,mortality and incidence in 17screening policy 16Italy,mortality and incidence in 17screening policy 16LBC, see under liquid-based cytologylife-years saved 50liquid-based cytology (LBC),cost-effectiveness of 51implications for screeningprogrammes using 51sensitivity of 51specificity of 51low-grade lesions, sensitivity of Pap smearfor 13mathematical models of vaccines 62Mexico, HPV testing plus cytology studiesin 31models,compartmental deterministic 65of epidemiological impact of vaccines62results for cervical cancer 69results for SIL 69simplifications used in 71mortality,decrease in with screening 15in Europe 17reduction with HPV testing pluscytology 30negative predictive value, of HPV testing54, 56the Netherlands,mortality and incidence in 17screening policy 16use of HPV testing for triage in BMD28Norway, mortality and incidence in 18organized cf opportunistic screening 19Pap smear,and performance of screening test 12effectiveness of 49key features of successful testingprogramme 50protective effect of 18, 19repeat smears 14sensitivity of 13, 38specificity of 13PAPNET 52Portugal,mortality and incidence in 17screening policy 16pre-cancerous lesions,identification by Pap smear 14spontaneous regression of 14prophylactic vaccines 62protocols required for screeningprogrammes 46psychological costs of screening 49public health,cervical cancer screening and 45–58impact of vaccines on 61–76public health policies 12quality of life issues 49quality-adjusted life years 49recommendations for ASCUS-positiveHPV-negative women 54regression,of BMD 37of CIN 1 and CIN 2 lesions 36rates of for SIL 68spontaneous 14screening,algorithm for 46, 4781